Advanced Solid Tumor Clinical Trial
Official title:
A Phase I/II, Open-Label, Multiple Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-102 Monotherapy or Combination Therapy in Patients With CLDN18.2-Positive Advanced Solid Tumors
Verified date | March 2023 |
Source | LaNova Medicines Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open label Phase I/II trial of LM-102 injection, a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2). It is being tested in advanced solid tumors including gastric cancer/gastroesophageal junction adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, esophageal adenocarcinoma and ovarian mucous carcinoma.
Status | Terminated |
Enrollment | 11 |
Est. completion date | February 28, 2023 |
Est. primary completion date | February 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: Subjects will be enrolled into the study only if they meet all of the following inclusion criteria: 1. Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the informed consent document prior to any procedure; 2. Aged between 18 to 75 years old, male or female when sign the Informed consent form (ICF); 3. Subjects who meet the criteria: Phase I dose escalation: Part Ia: Subjects have histological or cytological confirmation of recurrent or refractory advanced solid tumors, and are intolerable for available standard therapy, or there is no available standard therapy. Part Ib:Subjects have been histologically or cytologically confirmed advanced solid tumors and meet the criteria as follows: No previous systemic chemotherapy was given for the recurrent or metastatic disease or for the subjects who have received curative treatment (including neo-adjuvant or adjuvant chemotherapy /radiotherapy, etc.), the interval between recurrence and the last dose of previous anti-cancer treatment must be more than 6 months. Phase II dose expansion: subjects with positive CLDN18.2 confirmed by central immunohistochemistry (IHC). Part IIa: Subjects have histological or cytological confirmation of recurrent or refractory advanced solid tumors, and are intolerable for available standard therapy, or there is no available standard therapy. Part IIb: Subjects have histological or cytological confirmation of advanced solid tumors and meet the criteria as follows: No previous systemic chemotherapy was given for the recurrent or metastatic disease, or for the subjects who have received curative treatment (including neo-adjuvant or adjuvant chemotherapy /radiotherapy, etc.), the interval between recurrence and the last dose of previous anti-cancer treatment must be more than 6 months; 4. At least one evaluable lesion for phase I and one measurable lesion for phase II according to RECIST v1.1; 5. ECOG score 0-1; 6. Life expectancy = 3 months; 7. Subjects must have the following organ and marrow function in laboratory tests within 7 days prior to the first dose; 8. Subjects who are able to well communicate with investigators as well as understand and adhere to the requirements of this study. Exclusion Criteria: Subjects will be excluded from the study, if they meet any of the following criteria: 1. Child-bearing potential female who have positive results in pregnancy test or are lactating; 2. Subjects who known to be allergic to the similar products or any of its excipients; 3. Exposure to any IMP, or participate in any other clinical trial within 21 days prior to 1st dosing of LM-102; 4. Subjects with anti-tumor treatment within 28 days prior to 1st dosing of LM-302, including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy, etc. 5. Subjects who have received surgical or interventional treatment within 28 days prior to 1st dosing LM-102, with the exception for tumor biopsy, puncture, etc.; 6. Subjects who have received the treatment targeting to CLDN18.2 or ADCs; 7. Use of any live vaccines (e.g., against infectious diseases such as influenza, varicella etc.) within 28 days prior to 1st dosing of LM-102; 8. Subjects with the history of interstitial lung disease or drug-induced interstitial lung disease/pneumonitis; 9. Subjects who are taking therapeutic doses of anticoagulants such as heparin or vitamin K antagonists (except for preventive treatment at a stable dose); 10. Subjects with gastric outlet obstruction, persistent recurrent vomiting or uncontrolled/severe gastrointestinal hemorrhage, or ulcer within 28 days prior to 1st dosing; 11. Subjects who are unable to take the oral drugs, have the conditions that severely affect gastrointestinal absorption; 12. Subjects with known central nervous system (CNS) or meningeal metastasis; 13. Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures; 14. Subjects who have severe cardiovascular disease; 15. Any adverse event from prior anti-tumor therapy has not yet recovered to = grade 1 of CTCAE v5.0; 16. Subjects with uncontrolled tumor-related pain. 17. Subjects who have uncontrolled or severe illness, including but not limited to ongoing or active infection requiring antibiotics administration; 18. Subjects who have a history of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, or organ transplantation, or allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation; 19. HIV infection, active HBV and HCV infection; 20. Men and women who are unwilling to use appropriate contraceptive methods throughout the study period and for at least 6 months after the last use of LM-102; 21. Subjects who have psychiatric illness or social situations that would preclude study compliance; 22. Subjects who have another active malignancy which is likely to require treatment, and have the history of another malignancy within 2 years before the first dosing; 23. Subject who is determined as not eligible to participate in this study by the investigator. |
Country | Name | City | State |
---|---|---|---|
China | Fudan Zhongshan Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
LaNova Medicines Development Co., Ltd. | First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Zhejiang University, Shanghai Zhongshan Hospital, Sir Run Run Shaw Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence and case number of DLT (Dose Limiting Toxicity) during observation period | DLT is short for Dose Limiting Toxicity. dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. | up to 21 days following first dose | |
Primary | Participant Safety as characterized by frequency and severity of adverse events(according to NCI CTCAE 5.0) | An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. | up to 31 days following last dose or other anti-cancer therapy | |
Primary | Recommended Phase II Dose (RP2D) | The RP2D will be determined during the dose expansion stage of the study. RP2D will be determined using available safety and efficacy data. | up to 21 days following first dose | |
Primary | Maximum Tolerated Dose (MTD) | The MTD is defined as the dose of which the toxicity rate is lower than the upper bound of EI p_T+?_1= 0.35 and closest to the target toxicity rate of p_T= 0.3 during the DLT observation period (21 days after the first administration in cycle 1 on day 1). | up to 21 days following first dose | |
Secondary | Area under plasma concentration vs time curve (AUC) for LM-102 | changes in AUC over time in participants with LM-102 | Up to finished circle 5 (each cycle is 21 days) | |
Secondary | Peak plasma concentration (Cmax) for LM-102 | Cmax is the maximum plasma concentration. | Up to finished circle 5 (each cycle is 21 days) | |
Secondary | Time to maximum observed plasma concentration (Tmax) | Tmax is the time in hrs/days it takes to reach Cmax after dosing with LM-102 | Up to finished circle 5 (each cycle is 21 days) | |
Secondary | Terminal elimination half life (t1/2) | Time for the plasma level of LM-102 to decrease by 1/2 during the terminal elimination phase | Up to finished circle 5 (each cycle is 21 days) | |
Secondary | Immunogenicity | by measurement of Incidence of anti-drug antibodies (ADA) | up to 31 days following last dose | |
Secondary | Disease Control Rate(DCR ) | as measured by RECIST v1.1 | through study completion, an average of 8 months. | |
Secondary | Duration of Response (DOR) | as measured by RECIST v1.1 | through study completion, an average of 8 months. | |
Secondary | Progression free survival (PFS) | as measured by RECIST v1.1 | through study completion, an average of 8 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT05508100 -
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05515185 -
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06007482 -
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06008366 -
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06054932 -
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06365918 -
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05461287 -
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05443126 -
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05569057 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
Phase 1 |